Stifel Financial’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$880K Buy
+20,798
New +$763K ﹤0.01% 2636
2022
Q1
– Sell
-9,828
Closed -$431K – 3433
2021
Q4
$431K Sell
9,828
-1,234
-11% -$58.4K ﹤0.01% 2676
2021
Q3
$561K Sell
11,062
-2,621
-19% -$137K ﹤0.01% 2514
2021
Q2
$712K Buy
13,683
+1,067
+8% +$50.1K ﹤0.01% 2357
2021
Q1
$577K Sell
12,616
-24,618
-66% -$1.2M ﹤0.01% 2389
2020
Q4
$1.71M Sell
37,234
-906
-2% -$39.1K ﹤0.01% 1491
2020
Q3
$1.49M Buy
38,140
+10,875
+40% +$418K ﹤0.01% 1383
2020
Q2
$1.04M Buy
+27,265
New +$920K ﹤0.01% 1534

Other funds holding IDNA

Stifel Financial's IDNA Position: Q3 2026 in Review

Stifel Financial opened a new position in iShares Genomics Immunology and Healthcare ETF (IDNA) in Q3 2026: 20,798 shares worth $880K. The stake represents ﹤0.01% of the portfolio and ranks #2636 among its holdings. This is a return to the name: Stifel Financial previously reported a position in IDNA as recently as Q4 2021.

Stifel Financial first reported a position in IDNA in Q2 2020 and has held it in 8 quarters since. The position peaked at $1.71M in Q4 2020. 81 funds tracked by Wall St. Rank hold IDNA as of Q3 2026.

  • Stifel Financial held 20,798 shares of iShares Genomics Immunology and Healthcare ETF worth $880K as of Q3 2026.
  • iShares Genomics Immunology and Healthcare ETF was a new Stifel Financial position in Q3 2026.
  • iShares Genomics Immunology and Healthcare ETF made up ﹤0.01% of Stifel Financial's portfolio in Q3 2026, its #2636 holding.
  • Stifel Financial first reported a position in iShares Genomics Immunology and Healthcare ETF in Q2 2020 and has held it in 8 quarters since.
  • Stifel Financial's iShares Genomics Immunology and Healthcare ETF position peaked at $1.71M in Q4 2020.
  • 81 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q3 2026.

Based on Stifel Financial's 13F filing for Q3 2026, filed 12 Nov 2026.